SNTI
NASDAQSenti Biosciences Inc.
Price$0.44+0.00 (+0.74%)
07:30 PM07:45 PM
News · 26 weeks49+150%
2026-01-182026-07-12
Mix2990d
- SEC Filings19(66%)
- Other8(28%)
- Earnings2(7%)
Latest news
25 items- SECAmendment: SEC Form S-3/A filed by Senti Biosciences Inc.S-3/A - Senti Biosciences Holdings, Inc. (0001854270) (Filer)
- SECSEC Form DEFA14A filed by Senti Biosciences Inc.DEFA14A - Senti Biosciences Holdings, Inc. (0001854270) (Filer)
- SECSenti Biosciences Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Results of Operations and Financial Condition, Changes in Control of Registrant, Regulation FD Disclosure, Other Events, Financial Statements and Exhibits8-K - Senti Biosciences Holdings, Inc. (0001854270) (Filer)
- PRSenti Biosciences Holdings, Inc. Announces a Strategic Transaction to Unlock Value for its Gene-Circuit-Enabled Pipeline, Including SENTI-202, and to Sharpen its Focus on Next-Generation Controllable Genetic Medicines Powered by its Regulator Dial™ Technology PlatformSenti Biosciences Holdings, Inc. to Advance Controllable Cell and Gene Therapies Leveraging the Regulator Dial Platform™Spin-off of Senti Biosciences, Inc., including SENTI-202, Aims to Unlock Value via Contingent Value Right to Potential Future Milestone Payments of up to $60 Million for Logic-Gated SENTI-202 Development and Commercialization SOUTH SAN FRANCISCO, Calif., July 15, 2026 (GLOBE NEWSWIRE) -- Senti Biosciences Holdings, Inc. (NASDAQ:SNTI) ("SBH" or the "Company") today announced a strategic transaction designed to sharpen its focus on next-generation controllable genetic medicines powered by its Regulator Dial™ technology platform (the "Retained Assets") and unlock value for
- PRThe Radoff-JEC Group Releases Presentation Highlighting Why Seer, Inc. Stockholders Should Vote for Boardroom ChangeDetails How Chair and CEO Omid Farokhzad, M.D., Compensation Committee Chair Terrance McGuire and Director Deep Nishar Have Burned More Than $310 Million in Cash, Adopted an Anti-Stockholder Poison Pill and Paid Themselves Excessively While Overseeing a 97% Decline in Seer’s Share Price Urges Stockholders to Elect Howard H. Berman, Ph.D., Joshua S. Horowitz and Luis E. Rinaldini to Help Prevent Further Value Destruction Bradley L. Radoff and Michael Torok (together with certain of their affiliates, the "Radoff-JEC Group" or "we"), who collectively own approximately 7.7% of the outstanding shares of Seer, Inc. (NASDAQ:SEER) ("Seer" or the "Company"), today released a presentation detaili
- SECSEC Form S-3 filed by Senti Biosciences Inc.S-3 - Senti Biosciences Holdings, Inc. (0001854270) (Filer)
- SECSenti Biosciences Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation, Financial Statements and Exhibits8-K - Senti Biosciences Holdings, Inc. (0001854270) (Filer)
- SECSEC Form 10-Q filed by Senti Biosciences Inc.10-Q - Senti Biosciences Holdings, Inc. (0001854270) (Filer)
- SECSenti Biosciences Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Other Events, Financial Statements and Exhibits8-K - Senti Biosciences Holdings, Inc. (0001854270) (Filer)
- PRSenti Biosciences Holdings Reports First Quarter 2026 Financial Results and Highlights Advancement of SENTI-202 Program into Pivotal PhaseSecured strategic financing vehicle for up to $40 million Positive FDA feedback supports single-arm pivotal trial for potential registration of SENTI-202 in initial indication of Relapsed/Refractory Acute Myeloid Leukemia (R/R AML)Continued operational streamlining contributed to substantially reduced quarterly net loss and cash burn SOUTH SAN FRANCISCO, Calif., May 14, 2026 (GLOBE NEWSWIRE) -- Senti Biosciences Holdings, Inc. (NASDAQ:SNTI) (Senti Bio), a clinical-stage biotechnology company developing next-generation cell and gene therapies using its proprietary Gene Circuit platform, today reported financial results for the first quarter ended March 31, 2026, and provided recent busin
- PRSenti Biosciences Holdings Announces Positive FDA RMAT Meeting on Registrational Clinical and CMC Strategy for SENTI-202 in Relapsed/Refractory AML, Along with Important Efficacy and Durability Updates on the SENTI-202 Clinical ProgramFollowing a Type B meeting with FDA, Senti Bio plans to proceed with a single-arm multi-center registrational trial for SENTI-202, building off the strong Phase 1 clinical results demonstrating deep and durable MRD-negative complete remissions To further optimize SENTI-202 efficacy, the selection criteria for donors for all future manufacturing will include the "Donor X" phenotype Phase 1 clinical trial patients receiving SENTI-202 from Donor X-derived NK cells achieved a 50% composite CR (cCR) rate SOUTH SAN FRANCISCO, Calif., May 14, 2026 (GLOBE NEWSWIRE) -- Senti Biosciences Holdings, Inc. (NASDAQ:SNTI) ("Senti Bio" or the "Company"), a clinical-stage biotechnology company developing
- SECSEC Form 15-12G filed by Senti Biosciences Inc.15-12G - Senti Biosciences, Inc. (0001854270) (Filer)
- SECSEC Form 424B5 filed by Senti Biosciences Inc.424B5 - Senti Biosciences, Inc. (0001854270) (Filer)
- SECSenti Biosciences Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation, Unregistered Sales of Equity Securities, Changes in Control of Registrant, Financial Statements and Exhibits8-K - Senti Biosciences, Inc. (0001854270) (Filer)
- SECSEC Form EFFECT filed by Senti Biosciences Inc.EFFECT - Senti Biosciences, Inc. (0001854270) (Filer)
- SECSEC Form EFFECT filed by Senti Biosciences Inc.EFFECT - Senti Biosciences, Inc. (0001854270) (Filer)
- SECSEC Form EFFECT filed by Senti Biosciences Inc.EFFECT - Senti Biosciences, Inc. (0001854270) (Filer)
- SECSEC Form EFFECT filed by Senti Biosciences Inc.EFFECT - Senti Biosciences, Inc. (0001854270) (Filer)
- SECAmendment: SEC Form 10-K/A filed by Senti Biosciences Inc.10-K/A - Senti Biosciences, Inc. (0001854270) (Filer)
- SECSEC Form S-8 filed by Senti Biosciences Inc.S-8 - Senti Biosciences, Inc. (0001854270) (Filer)
- SECSEC Form S-8 POS filed by Senti Biosciences Inc.S-8 POS - Senti Biosciences, Inc. (0001854270) (Filer)
- SECSEC Form S-8 POS filed by Senti Biosciences Inc.S-8 POS - Senti Biosciences, Inc. (0001854270) (Filer)
- SECSEC Form S-8 POS filed by Senti Biosciences Inc.S-8 POS - Senti Biosciences, Inc. (0001854270) (Filer)
- SECSEC Form S-8 POS filed by Senti Biosciences Inc.S-8 POS - Senti Biosciences, Inc. (0001854270) (Filer)
- SECSEC Form POS AM filed by Senti Biosciences Inc.POS AM - Senti Biosciences, Inc. (0001854270) (Filer)
SNTI FAQ
6 questionsWhere does SNTI stock trade?
Senti Biosciences Inc. (SNTI) is listed on NASDAQ.What sector and industry is SNTI in?
Senti Biosciences Inc. operates in the Health Care sector, Biotechnology: Biological Products (No Diagnostic Substances) industry.When did Senti Biosciences Inc. go public?
Senti Biosciences Inc. (SNTI) completed its IPO in 2021.What are analysts saying about SNTI?
Senti Biosciences Inc. has had 3 recent analyst actions on file. The most recent action was from H.C. Wainwright: Buy with a $1200.00 price target on 2025-10-14. Recent price targets range from $500.00 to $1200.00.What companies are similar to SNTI?
Notable peers in the same industry include AMGN (Amgen Inc.), GILD (Gilead Sciences Inc.), ARGX (argenx SE), RVMD (Revolution Medicines Inc.), BIIB (Biogen Inc.). Compare SNTI side-by-side with any of them on Quantisnow.How can I track SNTI on Quantisnow?
Quantisnow aggregates Senti Biosciences Inc.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow SNTI to receive live email and push alerts on every new disclosure.